Systems analysis of BCL2 protein family interactions establishes a model to predict responses to chemotherapy

Cancer Research

Volumn 73, Issue 2, 2013, Pages 519-528

  Lindner, Andreas U ^a   Concannon, Caoimhín G ^a   Boukes, Gerhardt J ^a   Cannon, Mary D ^a,b   Llambi, Fabien ^c   Ryan, Deborah ^a,b   Boland, Karen ^a,b   Kehoe, Joan ^a,b   McNamara, Deborah A ^b   Murray, Frank ^b   Kay, Elaine W ^b   Hector, Suzanne ^a   Green, Douglas R ^c   Huber, Heinrich J ^a   Prehn, Jochen H M ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL STRESS; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MATHEMATICAL MODEL; MITOCHONDRION; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN INTERACTION; SYSTEM ANALYSIS;

AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; COMPUTATIONAL BIOLOGY; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; PROTEIN ARRAY ANALYSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SYSTEMS ANALYSIS; TREATMENT OUTCOME;

EID: 84872503488     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2269     Document Type: Article

References (47)

1. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000;256: 42-9.
2. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004;23: 2934-49.
3. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
4. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007;26: 1324-37.
5. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407: 770-6.
6. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001;292: 727-30.
7. Leber B, Lin J, Andrews DW. Embedded together: the life and death consequences of interaction of the Bcl-2 family with membranes. Apoptosis 2007;12: 897-911.
8. Hector S, Prehn JH. Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer: a review. Biochim Biophys Acta 2009;1795: 117-29.
9. Buglioni S, D'Agnano I, Cosimelli M, Vasselli S, D'Angelo C, Tedesco M, et al. Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role of p53 and bcl-2. Int J Cancer 1999;84: 545-52.
10. Manne U, Weiss HL, Grizzle WE. Bcl-2 expression is associated with improved prognosis in patients with distal colorectal adenocarcinomas. Int J Cancer 2000;89: 423-30.
11. Sinicrope FA, Hart J, Michelassi F, Lee JJ. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res 1995;1: 1103-10.
12. Huber HJ, Duessmann H, Wenus J, Kilbride SM, Prehn JH. Mathematical modelling of the mitochondrial apoptosis pathway. Biochim Biophys Acta 2011;1813: 608-15.
13. Dussmann H, Rehm M, Concannon CG, Anguissola S, Wurstle M, Kacmar S, et al. Single-cell quantification of Bax activation and mathematical modelling suggest pore formation on minimal mitochondrial Bax accumulation. Cell Death Differ 2010;17: 278-90.
14. Rehm M, Huber HJ, Dussmann H, Prehn JH. Systems analysis of effector caspase activation and its control by X-linked inhibitor of apoptosis protein. EMBO J 2006;25: 4338-49.
15. Albeck JG, Burke JM, Aldridge BB, Zhang M, Lauffenburger DA, Sorger PK. Quantitative analysis of pathways controlling extrinsic apoptosis in single cells. Mol Cell 2008;30: 11-25.
16. Schmid J, Dussmann H, Boukes GJ, Flanagan L, Lindner AU, O'Connor CL, et al. Systems analysis of cancer cell heterogeneity in caspasedependent apoptosis subsequent to mitochondrial outer membrane permeabilisation. J Biol Chem 2012;287: 41546-59.
17. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005;17: 393-403.
18. Hector S, Rehm M, Schmid J, Kehoe J, McCawley N, Dicker P, et al. Clinical application of a systems model of apoptosis execution for the prediction of colorectal cancer therapy responses and personalisation of therapy. Gut 2012;61: 725-33.
19. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91: 231-41.
20. Puthalakath H, Villunger A, O'Reilly LA, Beaumont JG, Coultas L, Cheney RE, et al. Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science 2001;293: 1829-32.
21. Ekoff M, Kaufmann T, Engstrom M, Motoyama N, Villunger A, Jonsson JI, et al. The BH3-only protein Puma plays an essential role in cytokine deprivation induced apoptosis of mast cells. Blood 2007;110: 3209-17.
22. Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, Ausserlechner MJ, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003;302: 1036-8.
23. Hershko T, Ginsberg D. Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J Biol Chem 2004;279: 8627-34.
24. Sunters A, Fernandez de Mattos S, Stahl M, Brosens JJ, Zoumpoulidou G, Saunders CA, et al. FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem 2003;278: 49795-805.
25. Kubota Y, Kinoshita K, Suetomi K, Fujimori A, Takahashi S. Mcl-1 depletion in apoptosis elicited by ionizing radiation in peritoneal resident macrophages of C3H mice. J Immunol 2007;178: 2923-31.
26. Martinez-Caballero S, Dejean LM, Kinnally MS, Oh KJ, Mannella CA, Kinnally KW. Assembly of the mitochondrial apoptosis-induced channel, MAC. J Biol Chem 2009;284: 12235-45.
27. Bleicken S, Classen M, Padmavathi PV, Ishikawa T, Zeth K, Steinhoff HJ, et al. Molecular details of Bax activation, oligomerization, and membrane insertion. J Biol Chem 2010;285: 6636-47.
28. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10: 389-99.
29. Laughton MJ, Halliwell B, Evans PJ, Hoult Jr. Antioxidant and prooxidant actions of the plant phenolics quercetin, gossypol and myricetin. Effects on lipid peroxidation, hydroxyl radical generation and bleomycin-dependent damage to DNA. Biochem Pharmacol 1989;38: 2859-65.
30. Llambi F, Moldoveanu T, Tait SW, Bouchier-Hayes L, Temirov J, McCormick LL, et al. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol Cell 2011;44: 517-31.
31. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001;7: 683-94.
32. de Bruijn MT, Raats DA, Hoogwater FJ, van Houdt WJ, Cameron K, Medema JP, et al. Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa. Br J Cancer 2010;102: 1254-64.
33. Happo L, Cragg MS, Phipson B, Haga JM, Jansen ES, Herold MJ, et al. Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim. Blood 2010;116: 5256-67.
34. O'Reilly LA, Print C, Hausmann G, Moriishi K, Cory S, Huang DC, et al. Tissue expression and subcellular localization of the pro-survival molecule Bcl-w. Cell Death Differ 2001;8: 486-94.
35. Vogler M. BCL2A1: the underdog in the BCL2 family. Cell Death Differ 2012;19: 67-74.
36. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006;9: 351-65.
37. Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011;334: 1129-33.
38. Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008;7: 989-1000.
39. Olgiati KL, Toscano WA Jr. Kinetics of gossypol inhibition of bovine lactate dehydrogenase X. Biochem Biophys Res Commun 1983;115: 180-5.
40. Wei J, Kitada S, Rega MF, Stebbins JL, Zhai D, Cellitti J, et al. Apogossypol derivatives as pan-active inhibitors of antiapoptotic Bcell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem 2009;52: 4511-23.
41. Vogler M, Weber K, Dinsdale D, Schmitz I, Schulze-Osthoff K, Dyer MJ, et al. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 2009;16: 1030-9.
42. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther 2010;87: 272-7.
43. Rubin EH, Gilliland DG. Drug development and clinical trials-the path to an approved cancer drug. Nat Rev Clin Oncol 2012;9: 215-22.
44. Hennessy BT, Lu Y, Gonzalez-Angulo AM, Carey MS, Myhre S, Ju Z, et al. A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Clin Proteomics 2010;6: 129-51.
45. Krajewska M, Kim H, Kim C, Kang H, Welsh K, Matsuzawa S, et al. Analysis of apoptosis protein expression in early-stage colorectal cancer suggests opportunities for new prognostic biomarkers. Clin Cancer Res 2005;11: 5451-61.
46. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144: 646-74.
47. Huber HJ, Dussmann H, Kilbride SM, Rehm M, Prehn JH. Glucose metabolism determines resistance of cancer cells to bioenergetic crisis after cytochrome-c release. Mol Syst Biol 2011;7: 470.